Novel Therapeutics
Drug with New Formulations
Remsina SC, or subcutaneous formulation of infliximab, is the next generation flagship product developed by Celltrion. So far, its dosing method patent and formulation patent application are completed in over 130 countries, securing firm foundation for exclusivity in the infliximab market over the next 20 years. The self-administration of Remsima SC can offer convenience for patients and increase their quality of life. Recently, Celltrion filed for US FDA approval for the sale of Remsima SC to enter the US market.Antibody-based Modalities
Antibody-Drug Conjugates (ADCs) target cancer cells over healty cells via delivering chemotherapy agents. Bispecific or multispecific antibodies can efficiently modulate multiple targets at once. Celltrion is engaging in open innovation and joint development projects with global pharmaceutical companies to develop novel drugs including ADC and biobetters for various target diseases (breast cancer, etc).